Soft Contact Lenses Market: as CooperVision secures Japanese regulatory authorisation for MiSight 1 day, the first soft contact lens in Japan permitted specifically for myopia control in children, the company is opening the world's second-largest ophthalmic device market to a therapeutic category that barely existed commercially five years ago, so the addressable myopia control patient population is expanding geographically at precisely the moment the underlying pandemic-driven myopia prevalence trend continues accelerating across East Asia.

The global soft contact lenses market size was USD 13.04 Billion in 2025 and is expected to register a revenue CAGR of 6.2% during the forecast period. Market revenue growth is driven by factors such as the global myopia prevalence increase driving sustained demand for corrective and myopia control lens technology, silicone hydrogel material adoption improving comfort and oxygen permeability across daily wear categories, and international regulatory expansion of myopia control lens technology opening new addressable geographic markets. The first driving factor is the global myopia prevalence increase, often described as a myopia pandemic, which directly expands the population requiring both corrective and specifically myopia-control-focused contact lens technology. Daily disposable lenses account for a substantial share of total 2025 market revenue, reflecting this modality's continued growth as the preferred wearing schedule across an expanding range of lens categories. The second driving factor is silicone hydrogel material adoption, which improves comfort and oxygen permeability relative to conventional hydrogel materials, supporting extended and more comfortable daily wear. The third driving factor is international regulatory expansion of myopia control lens technology, as manufacturers secure new-market regulatory authorisation for products with an established clinical evidence base in their home markets. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single myopia control lens platform's international regulatory authorisation converts a therapeutic technology validated in one market into an immediately addressable new patient population in a market with a documented, often more severe, underlying myopia prevalence rate, which lets the manufacturer capture new demand without needing to develop new clinical evidence from scratch. Because myopia control lens technology's clinical evidence base is established primarily through the manufacturer's home-market clinical trials and post-market data, securing new-market regulatory authorisation lets that same validated technology address a new country's paediatric myopia population without requiring an entirely new clinical development programme, so international authorisation converts existing clinical investment into meaningfully expanded addressable market with high incremental efficiency. As a result, demand and revenue share in the myopia control category are concentrating around manufacturers with the broadest international regulatory footprint, and the forecast reflects this geographic expansion dynamic as a distinct driver of the market's fastest-growing lens category. For instance, in August 2025, CooperVision received Ministry of Health, Labour and Welfare approval in Japan for MiSight 1 day, the first soft contact lens in Japan authorised specifically for myopia control in children, extending a technology platform already validated through five years of FDA-approved use in the United States. These are some of the key factors driving revenue growth of the market.

Because contact lens wear requires consistent hygiene compliance and appropriate lens care practices to avoid corneal complications, patients with documented compliance challenges or certain ocular surface conditions face genuine clinical limitations on contact lens candidacy regardless of how advanced the underlying lens material or design technology becomes.

Price competition in commodity spherical daily disposable lens categories compressing margin for standard products is a second constraint, since the most basic spherical daily disposable lens category has become increasingly commoditised across manufacturers, which continues to compress margin in this high-volume segment even as premium categories like myopia control and multifocal lenses command meaningfully stronger pricing power.

Regulatory and reimbursement variability for myopia control technology across international markets is a third constraint, since coverage and regulatory pathway clarity for myopia control lens technology specifically varies significantly by country, which creates inconsistent adoption incentives even where clinical evidence supports expanded paediatric myopia control use.

These factors substantially limit soft contact lenses market growth over the forecast period.

The clearest driver of demand is the global myopia prevalence increase, often described as a myopia pandemic, which directly expands the population requiring both corrective and specifically myopia-control-focused contact lens technology. Rising myopia prevalence, particularly pronounced across East Asian populations and increasingly documented in Western markets as well, represents a well-documented public health trend independent of any single manufacturer's product strategy, so baseline soft contact lens demand tracks this demographic and epidemiological trend directly. Daily disposable lenses account for a substantial share of total 2025 market revenue, and CooperVision marked the five-year anniversary of FDA approval for MiSight 1 day, the only FDA-approved myopia control soft contact lens for children aged 8 to 12 in the United States, reflecting a now well-established clinical evidence and commercial track record. The effect on the market is that myopia control has moved from an emerging therapeutic category into a demonstrated, multi-year commercial success that manufacturers are now actively extending into new geographic markets. These are some of the key factors driving revenue growth of the market.

The second driver is silicone hydrogel material adoption, which improves comfort and oxygen permeability relative to conventional hydrogel materials, supporting extended and more comfortable daily wear across an expanding range of lens categories. A conventional hydrogel lens material provides meaningfully less oxygen permeability to the cornea than silicone hydrogel, so the continued shift toward silicone hydrogel across daily disposable, toric, and multifocal categories directly improves wearer comfort and reduces complication risk associated with reduced corneal oxygenation during extended wear. Alcon expanded its PRECISION1 daily disposable silicone hydrogel portfolio with new add-on powers for presbyopia correction, extending the platform specifically into the presbyopia management segment, while Johnson and Johnson Vision launched ACUVUE OASYS MAX 1-Day multifocal for astigmatism, the first daily disposable lens addressing presbyopia patients with concurrent astigmatism. The effect on the market is that silicone hydrogel material adoption continues extending into increasingly specialised lens categories beyond standard spherical correction, capturing patients with more complex vision correction needs. These are some of the key factors driving revenue growth of the market.

CooperVision's August 2025 MHLW approval makes MiSight 1 day the first soft contact lens in Japan authorised specifically for myopia control in children, extending a platform already validated through five years of FDA-approved US use. This opens the world's second-largest ophthalmic device market to a therapeutic category still expanding its international regulatory footprint.

The third driver is international regulatory expansion of myopia control lens technology, as manufacturers secure new-market regulatory authorisation for products with an already-established clinical evidence base in their home markets. A myopia control lens technology's clinical evidence base, once established through years of home-market clinical trials and post-market surveillance data, transfers substantially to a new geography once regulatory authorisation is obtained, converting prior clinical development investment into meaningfully expanded addressable market. In August 2025, CooperVision received MHLW approval in Japan for MiSight 1 day, the first soft contact lens in Japan authorised specifically for myopia control in children, opening a market with among the highest documented paediatric myopia prevalence rates globally. The effect on the market is that myopia control lens technology's addressable patient population is expanding geographically at a pace that outstrips what any single home market's demographic growth alone could support. These are some of the key factors driving revenue growth of the market.

However, the soft contact lenses market faces severe adoption constraints from lens care compliance and hygiene-related complications limiting broader adoption among certain patient populations, and price competition in commodity spherical daily disposable lens categories compressing margin for standard, non-differentiated products.

Because contact lens wear requires consistent hygiene compliance and appropriate lens care practices to avoid corneal complications, patients with documented compliance challenges or certain ocular surface conditions face genuine clinical limitations on contact lens candidacy regardless of how advanced the underlying lens material or design technology, including newer silicone hydrogel platforms, becomes.

Price competition in commodity spherical daily disposable lens categories compressing margin for standard products compounds this, since the most basic spherical daily disposable lens category has become increasingly commoditised across manufacturers, which continues to compress margin in this high-volume segment even as premium categories like CooperVision's newly Japan-authorised MiSight command meaningfully stronger pricing power.

Regulatory and reimbursement variability for myopia control technology across international markets is the third constraint, since coverage and regulatory pathway clarity for myopia control lens technology specifically varies significantly by country, which creates inconsistent adoption incentives even where clinical evidence supports expanded paediatric myopia control use.

These factors substantially limit soft contact lenses market growth over the forecast period.

Based on lens type, the global soft contact lenses market is segmented into spherical, toric, multifocal and presbyopia, and myopia control lenses. Spherical soft contact lenses hold the largest revenue share, because standard myopic and hyperopic correction represents the broadest and most universally applicable vision correction need across the global contact lens wearer population, which suits a market where the most widely applicable correction category commands the largest revenue category. Toric lenses remain an important, established category for astigmatism correction. Myopia control lenses are expected to register the fastest revenue growth rate in the global soft contact lenses market over the forecast period, driven by CooperVision's August 2025 Japan MHLW approval and comparable international regulatory expansion.

Based on material, the global soft contact lenses market is segmented into silicone hydrogel, conventional hydrogel, and hybrid or smart materials. Silicone hydrogel holds the largest revenue share, because it offers superior oxygen permeability and comfort relative to conventional hydrogel materials, which ties directly back to the material adoption dynamic described in the market's primary demand driver. Hybrid and smart materials are expected to register the fastest revenue growth rate in the global soft contact lenses market over the forecast period, driven by Bausch and Lomb's disclosed biomimetic lens development pipeline mimicking the natural structure of the eye.

Daily disposable modality is expected to account for the largest revenue share in the global soft contact lenses market during the forecast period

Based on modality, the global soft contact lenses market is segmented into daily disposable, bi-weekly disposable, and monthly disposable wearing schedules. Daily disposable holds the largest revenue share, because it eliminates lens care compliance requirements entirely while offering the strongest hygiene profile among wearing modalities. Daily disposable is also expected to register the fastest revenue growth rate in the global soft contact lenses market over the forecast period, driven by expanding daily disposable multifocal and myopia control product introductions from Alcon, Johnson and Johnson Vision, and CooperVision.

Based on regional analysis, the soft contact lenses market in North America accounted for largest revenue share in 2025. The United States leads because CooperVision's five-year FDA-approved MiSight track record and the concentration of Alcon's, Johnson and Johnson Vision's, and CooperVision's primary commercial presence create the deepest and most established contact lens demand globally. The concentration of FDA clearance activity in the country also means new lens technology categories, including myopia control, are typically established in the United States first before international regulatory expansion follows.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent significant national markets within Europe. The result is steady rather than rapid growth, shaped more by national optical retail distribution structures than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan and China represent two of the largest national markets within the region, with Japan specifically anchoring CooperVision's August 2025 MiSight MHLW approval and China representing among the highest documented paediatric myopia prevalence rates globally. The region's exceptionally high myopia prevalence leaves considerably more room for growth than in the already contact-lens-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding optical retail infrastructure driving early advanced lens technology demand growth. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the specialised silicone hydrogel polymer materials that Latin American contact lens manufacturers depend on, an effect expected to run through 2026 and slow soft contact lenses adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding optical retail network and the UAE's regional distribution hubs represent the primary investment centres for soft contact lenses adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the ophthalmology and optometry infrastructure needed to support advanced lens technology at scale.